SKYSCRAPER-02, the first randomized study of tiragolumab in ES-SCLC, did not meet co-primary endpoint of PFS, Genentech says

Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked. A study led by researchers at Washington University School of Medicine in St. Louis takes a deep dive into inherited cancer mutations measured in a healthy blood sample and reports how those mutations might take a toll on the body’s cells starting at birth, perhaps predisposing a person to develop cancers at various stages of life.